Concepedia

Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

Yun Oh, Román Pérez-Soler, Frank V. Fossella, Bonnie S. Glisson, Jonathan M. Kurie, Garrett L. Walsh, Mylene T. Truong, Dong M. Shin

Investigational New Drugs · 2000 · 30 citations · 5 references

DOI

Concepts

References

5

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

Daniel D. Von Hoff · Annals of Internal Medicine · 1979 · 2.4K citations

, , +15

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients

David J. Sugarbaker, Raja M. Flores, Michael T. Jaklitsch et al. · Journal of Thoracic and Cardiovascular Surgery · 1999 · 986 citations · Full text

, , +15

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Franco M. Muggia, John D. Hainsworth, Susan Jeffers et al. · Journal of Clinical Oncology · 1997 · 657 citations

, , +17

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

Beatrice Uziely, Susan Jeffers, Rut Isacson et al. · Journal of Clinical Oncology · 1995 · 478 citations

, , +15

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

Dong M. Shin, Frank V. Fossella, Theera Umsawasdi et al. · Cancer · 1995 · 42 citations

, , +15